| Research on | Investigator | Agency Full Name | Start Date | End Date | Project Title |
| Stroke/TIA | Askiel Bruno | NMT Medical, Inc. |
10/1/2003 |
9/30/2008 |
A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to a Presumed Paradoxical Em |
| Alzheimer’s | Martin Rhys Farlow | University of California, San Diego |
6/1/2005 |
9/1/2009 |
Alzheimer's Disease Neuroimaging Initiative (ADNI) |
| Alzheimer’s | Martin Rhys Farlow | University of California, San Diego |
12/1/2002 |
6/30/2008 |
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease |
| Alzheimer’s | Martin Rhys Farlow | University of California, San Diego |
7/1/2003 |
12/31/2008 |
A Randomized, Double-Blind, Placebo-Controlled Trial of Valporate to Attenuate the Progression of Alzheimer's Disease (AD) |
| Alzheimer’s | Martin Rhys Farlow | Eli Lilly and Company |
4/1/2006 |
3/31/2008 |
LY2062430: Multiple-Dose Safety in Subjects with Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers H8A-MC-LZAJ |
| Alzheimer’s | Ann Marie Hake | Elan Pharmaceuticals, Inc |
5/6/2005 |
3/31/2009 |
A Phase IIa,Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients with Mild to Moderate Alzheimer's Disease |
| Drug Addiction | Ann E.K. Kosobud | National Institute on Drug Abuse |
9/30/2005 |
8/31/2008 |
Role of Circadian Entrainment in Drug Intake and Abuse |
| Epilepsy | Omkar N. Markand | Indiana Family and Social Services Administration |
7/1/2006 |
9/30/2007 |
Epilepsy Clinic and Services |
| Multiple sclerosis | David H. Mattson | Acorda Therapeutics, Inc. |
2/15/2006 |
2/15/2010 |
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Famprldlne-SR In Subjects with Multiple Sclerosis who Participated In the MS-F203 Trial |
| Multiple sclerosis | David H. Mattson | Artielle Immuno Therapeutics, Inc. |
6/20/2006 |
6/6/2008 |
A Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation Study of the Safety of a Single Dose of RTL1000 Injection in Patients with Relapsing Remitting or Secondary Progressive (RRMS or SPMS) Multiple sclerosis (MS) |
| Multiple sclerosis | David H. Mattson | Berlex Laboratories, Inc. |
3/31/2004 |
3/31/2009 |
International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/Betaferon 250mcg (8MIU) |
| Multiple sclerosis | David H. Mattson | Biogen Idec Inc. |
12/1/2004 |
12/1/2007 |
An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803 |
| Multiple sclerosis | David H. Mattson | Genentech Inc. |
10/12/2004 |
6/30/2008 |
Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera/Rituxan) in Adults with Primary Progressive Multiple Sclerosis |
| Epilepsy | Vicenta Salanova | Medtronic, Inc. |
11/26/2003 |
6/30/2010 |
Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE) |
| Epilepsy | Vicenta Salanova | Neuropace, Inc. |
1/24/2006 |
1/23/2009 |
Responsive Neurostimulator (RNS)System Pivotal Clinical Investigation |
| Autism | Deborah Karras Sokol | Clarian Health Partners, Inc. |
3/1/2006 |
2/28/2008 |
Alzheimer Disease Markers in Autism and Fragile X |
| Perinatal Stroke/ Cerebral Palsy | Meredith R. Golomb | Clarian Health Partners, Inc. |
5/1/2004 |
1/31/2008 |
Motor Outcomes After Perinatal Stroke: Who Will Get Cerebral Palsy? |
| Parkinson Disease | Joanne M. Wojcieszek | NIH-NINDS | 12/1/2006 | 11/30/2007 | Parkinson Disease Neuroprotection Clinical Trial |
| Huntington’s Disease | Joanne M. Wojcieszek | University of Rochester |
4/1/2005 |
1/31/2008 |
A Multi-Center, Double-Blind Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion) in Patients with Mild to Moderate Huntington's Disease' |
| Autism | Deborah Karras Sokol | Clarian Health Partners, Inc. |
3/1/2006 |
2/28/2008 |
Pilot Early Intervention/Long Distance Learning in Autism |
| Fragile X | Deborah Karras Sokol | Clarian Health Partners, Inc. |
3/1/2006 |
2/28/2008 |
Alzheimer Disease Markers in Autism and Fragile X |
Research
